Benzinga | Jan 11, 2021 08:20AM EST

Infinity Pharmaceuticals To Present MARIO-275 Phase 2 Data In Patients Qith Advanced Urothelial Cancer At ASCO Genitourinary Cancers Symposium Feb. 11-13

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021. MARIO-275 is a randomized, placebo- controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo(r)) in platinum-refractory, I/O na?ve patients with advanced urothelial cancer over nivolumab monotherapy, which is approved in this setting.